Press Releases

Year

5/25/21

BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference

LAVAL, Quebec --(BUSINESS WIRE)--May 25, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders,

PDF Version

5/12/21

BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

LAVAL, Quebec --(BUSINESS WIRE)--May 12, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders,

PDF Version

5/10/21

BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights

- Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials on track, with topline results expected Q4 2021 - - Ended quarter with US$81.9 million in cash, cash equivalents and short-term investments; current cash position expected to be sufficient to fund operating plan until end of 2022 - LAVAL,

PDF Version

5/10/21

BELLUS Health to Present at the American Thoracic Society 2021 International Conference

LAVAL, Quebec --(BUSINESS WIRE)--May 10, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders,

PDF Version

4/13/21

BELLUS Health to Present at the Bloom Burton & Co. Healthcare Investor Conference

LAVAL, Quebec --(BUSINESS WIRE)--Apr. 13, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today

PDF Version

3/24/21

BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors

LAVAL, Quebec --(BUSINESS WIRE)--Mar. 24, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced

PDF Version

2/25/21

BELLUS Health Reports Year 2020 Financial Results and Business Highlights

- Initiated the Phase 2b SOOTHE clinical trial in refractory chronic cough; topline results expected Q4 2021 with an interim analysis expected in mid-2021 - - Initiated the Phase 2 BLUEPRINT clinical trial in chronic pruritus associated with atopic dermatitis; topline results expected Q4 2021 - -

PDF Version

2/22/21

BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences

LAVAL, Quebec --(BUSINESS WIRE)--Feb. 22, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced

PDF Version

1/14/21

BELLUS Health to Present at the Eleventh International Virtual Cough Symposium

LAVAL, Quebec --(BUSINESS WIRE)--Jan. 14, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today

PDF Version